Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection

Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection

Achieving HBsAg seroclearance is a key goal in treating chronic hepatitis B virus (HBV) infection but remains difficult with nucleos(t)ide analogues (NAs). Tenofovir alafenamide fumarate (TAF), a recommended NA for managing chronic HBV infection (CHB), has uncertain effects on HBsAg levels and poten...

Full description

Saved in:
Bibliographic Details
Main Authors: Kazuto Tajiri, Yuka Hayashi, Aiko Murayama, Nozomu Muraishi, Masami Minemura, Ichiro Yasuda
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Viruses
Subjects:
hepatitis B virus
tenofovir alafenamide fumarate
nucleos(t)ide analogue switching
HBsAg decrease
dyslipidemia
Online Access:https://www.mdpi.com/1999-4915/17/1/44
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items